{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:47:44Z","timestamp":1782470864127,"version":"3.54.5"},"reference-count":82,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>The emergence of immune checkpoint inhibitors, targeted therapies, CAR T-cell therapy, and antibody\u2013drug conjugates has transformed modern oncology, significantly improving survival across a wide range of malignancies. However, these advances have also introduced a growing spectrum of endocrine and metabolic complications, redefining the scope of endocrine practice. Therapy-induced endocrinopathies, including thyroid dysfunction, hypophysitis, adrenal insufficiency, diabetes, pancreatitis, dyslipidemia, gonadal dysfunction, and metabolic syndrome, are recognized as clinically significant and often long-lasting consequences of cancer treatment. Unlike classical endocrine disorders, these conditions frequently present abruptly, display atypical clinical patterns, and require complex multidisciplinary management. This review explores the evolving field of oncoendocrinology, focusing on the mechanisms, clinical manifestations, and management of endocrine toxicities associated with novel cancer therapies. We also discuss the long-term endocrine sequelae of cancer treatment and the growing need for structured survivorship care and endocrine surveillance. In addition, we discuss future directions in oncoendocrinology, including predictive biomarkers, the need for treatment standardization, integrated care models, survivorship surveillance, and precision-based approaches to endocrine care. As cancer survival continues to improve, early recognition and long-term management of endocrine complications are becoming essential to optimizing both quality of life and overall outcomes in cancer survivors.<\/jats:p>","DOI":"10.3390\/medsci14030347","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:43:57Z","timestamp":1782463437000},"page":"347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Rise of Oncoendocrinology: How Modern Cancer Therapies Are Reshaping Endocrine Practice"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-1575","authenticated-orcid":false,"given":"Nidha","family":"Shapoo","sequence":"first","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Metropolitan Hospital, New York Medical College, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noella","family":"Boma","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Metropolitan Hospital, New York Medical College, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Gotlieb","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Metropolitan Hospital, New York Medical College, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mattana","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Metropolitan Hospital, New York Medical College, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Belokovskaya","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Metropolitan Hospital, New York Medical College, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYC Health & Hospitals\/Metropolitan Hospital, New York Medical College, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jjco\/hyq035","article-title":"Progress in cancer chemotherapy with special stress on molecular-targeted therapy","volume":"40","author":"Saijo","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2640342","DOI":"10.1155\/2018\/2640342","article-title":"mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?","volume":"2018","author":"Kezic","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mishra, R., Patel, H., Alanazi, S., Kilroy, M.K., and Garrett, J.T. (2021). PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073464"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Liang, J., Hu, F., Li, J., Zhai, Y., Guo, X., Xu, J., Ye, X., and He, J. (2026). Spectrum and prognosis of CAR-T-related endocrine toxicity: Glucose\/calcium dysregulation, pituitary axis disorders, and overlap with CRS. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1786129"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Giovanella, L., Tuncel, M., Campenn\u00ec, A., Ruggeri, R.M., Huellner, M., and Petranovi\u0107 Ov\u010dari\u010dek, P. (2025). Endocrine Adverse Events Induced by Cancer Treatments: The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography. Cancers, 17.","DOI":"10.3390\/cancers17162651"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1530\/EC-20-0489","article-title":"Endocrine toxicity of cancer immunotherapy: Clinical challenges","volume":"10","author":"Anderson","year":"2021","journal-title":"Endocr. Connect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2213-8587(26)00027-6","article-title":"Secondary causes of diabetes: A crossroad of endocrinology and oncology","volume":"14","author":"Hee","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.beem.2022.101663","article-title":"The novel concept of \u201cOnco-Immuno-Endocrinology\u201d led to the discovery of new clinical entity \u201cparaneoplastic autoimmune hypophysitis\u201d","volume":"36","author":"Takahashi","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2217\/fon.13.75","article-title":"Cancer endocrinology through own experience: Areas for further thought and development. Interview by Natasha Galukande","volume":"9","author":"Berstein","year":"2013","journal-title":"Future Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eprac.2024.03.023","article-title":"Endocrinopathies Associated with Immune Checkpoint Inhibitor Use","volume":"30","author":"Kotwal","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"bqaa177","DOI":"10.1210\/endocr\/bqaa177","article-title":"The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability","volume":"162","author":"Ganguly","year":"2021","journal-title":"Endocrinology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2213-8587(24)00088-3","article-title":"Endocrine health in survivors of adult-onset cancer","volume":"12","author":"Jaschke","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/ERC-17-0036","article-title":"Paraneoplastic endocrine syndromes","volume":"24","author":"Dimitriadis","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e180349","DOI":"10.1001\/jamanetworkopen.2018.0349","article-title":"Endocrine Late Effects in Survivors of Cancer in Adolescence and Young Adulthood: A Danish Population-Based Cohort Study","volume":"1","author":"Jensen","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1200\/JCO.2025.43.16_suppl.12132","article-title":"Immune-related endocrinopathy in cancer patients receiving immune checkpoint inhibitor therapy in the nationwide prospective DIRECT cohort","volume":"43","author":"Awad","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_19","first-page":"3232","article-title":"Endogenous hormones as a major factor in human cancer","volume":"42","author":"Henderson","year":"1982","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Miki, Y. (2023). Hormone-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310830"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tem.2010.06.007","article-title":"The proliferating role of insulin and insulin-like growth factors in cancer","volume":"21","author":"Gallagher","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tins.2023.01.003","article-title":"How cancer hijacks the body\u2019s homeostasis through the neuroendocrine system","volume":"46","author":"Slominski","year":"2023","journal-title":"Trends Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.46747\/cfp.6804271","article-title":"Endocrine therapies for breast and prostate cancers: Essentials for primary care","volume":"68","author":"Chaput","year":"2022","journal-title":"Can. Fam. Physician"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","article-title":"Approach to the Patient with Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction","volume":"108","author":"Wright","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: A large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: A novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMra1901214","article-title":"Drug Effects on the Thyroid","volume":"381","author":"Burch","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e14623","DOI":"10.1200\/JCO.2025.43.16_suppl.e14623","article-title":"Clinical determinants and outcomes of hypothyroidism in immune checkpoint inhibitor (ICI) therapy","volume":"43","author":"Syed","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1210\/clinem\/dgaf260","article-title":"Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study","volume":"110","author":"Gao","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.eprac.2025.06.008","article-title":"Risk of Pituitary Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"31","author":"Li","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ejendo\/lvag031","article-title":"Distinct patterns of pituitary dysfunction in combination immunotherapy with nivolumab and ipilimumab","volume":"194","author":"Sakurai","year":"2026","journal-title":"Eur. J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bellastella, G., Carbone, C., Scappaticcio, L., Cirillo, P., Troiani, T., Morgillo, F., Vietri, M.T., Della Corte, C.M., De Falco, V., and Napolitano, S. (2021). Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 13.","DOI":"10.3390\/cancers13164036"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study","volume":"107","author":"Labadzhyan","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mathara Diddhenipothage, S.A.D., Warden, J., Herbert, K., Pofi, R., Joseph, R., Coupe, N., Payne, M., Tomlinson, J.W., and Turner, H.E. (2026). Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery. Clin. Endocrinol., ahead of print.","DOI":"10.1111\/cen.70137"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kopanos, S., Filippatos, C., Rousakis, P., Kostopoulos, I.V., Baxevanis, C.N., Tentolouris, A., Gavriatopoulou, M., Tsitsilonis, O., and Ntanasis-Stathopoulos, I. (2025). Prognostic Significance of Endocrine-Related Adverse Events in Patients with Melanoma, Non-Small Cell Lung Cancer and Urothelial Cancer After Treatment with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17223675"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: Lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J. Investig. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MED.0000000000000652","article-title":"Hypophysitis from immune checkpoint inhibitors: Challenges in diagnosis and management","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"van der Leij, S., Suijkerbuijk, K.P.M., van den Broek, M.F.M., Valk, G.D., Dankbaar, J.W., and van Santen, H.M. (2024). Differences in checkpoint-inhibitor-induced hypophysitis: Mono- versus combination therapy induced hypophysitis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1400841"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocr. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107050","DOI":"10.1016\/j.intimp.2020.107050","article-title":"Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event","volume":"89","author":"Deligiorgi","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care, 49, S27\u2013S49.","DOI":"10.2337\/dc26-S002"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hu, Q., Fan, Y., and He, P. (2026). Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: A systematic review and meta-analysis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1669492"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chen, Y., Wang, X., and Duan, S. (2026). Immune checkpoint inhibitor-associated diabetes mellitus: Mechanisms, clinical manifestations, and management strategies. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1679751"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc22-2202","article-title":"Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e70316","DOI":"10.1111\/dme.70316","article-title":"The clinical spectrum and causal relationship assessment of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): A retrospective observational study","volume":"43","author":"Li","year":"2026","journal-title":"Diabet. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhou, L., Yang, S., Li, Y., Xue, C., and Wan, R. (2024). A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: Incidence, clinical features, management, and prognosis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1448728"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lee, Y., Oh, D., Cho, S.H., Hong, S.M., and Song, T.J. (2026). Immune checkpoint inhibitor-related pancreatitis: A comprehensive review of epidemiology, pathophysiology, and management. J. Gastroenterol., ahead of print.","DOI":"10.1007\/s00535-026-02389-2"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Zhang, W., Pang, L., Zeng, L., Liu, S., and Liu, J. (2023). Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: A systematic review and meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1166299"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Huang, L., Wang, H., and Wu, N. (2025). Pancreatitis associated with immune checkpoint inhibitors: A pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1635372"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-20-0683","article-title":"THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors","volume":"184","author":"Fallahi","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/jcpt.13472","article-title":"Thyroid dysfunction related to vascular endothelial growth factor receptor tyrosine kinase inhibitors: A real-world study based on FAERS","volume":"46","author":"Liao","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1152\/ajpendo.00163.2022","article-title":"Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia","volume":"324","author":"Janssen","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mugiya, T., Mothibe, M., Khathi, A., Ngubane, P., and Sibiya, N. (2024). Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: A review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1355171"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s40618-023-02025-3","article-title":"Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test","volume":"46","author":"Valerio","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Monti, S., Fazzalari, B., Renzelli, V., Bongermino, C., Lioni, M.F., Deiana, M.G., Poggi, M., Mori, F., and Pugliese, G. (2026). Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1691740"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/TP.0b013e31824bf1f0","article-title":"Sirolimus-associated testicular toxicity: Detrimental but reversible","volume":"93","author":"Rovira","year":"2012","journal-title":"Transplantation"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sirico, M., D\u2019Angelo, A., Gianni, C., Casadei, C., Merloni, F., and De Giorgi, U. (2023). Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers, 15.","DOI":"10.3390\/cancers15030703"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Chen, P., Xia, Y., Lei, W., Zhong, S., Jiang, H., Ren, L., Qian, W., and Liu, H. (2022). Case report: Hashimoto\u2019s thyroiditis after CD19 chimeric antigen receptor T-cell therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.995496"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Long, R., Zuo, H., Tang, G., Zhang, C., Yue, X., Yang, J., Luo, X., Deng, Y., Qiu, J., and Li, J. (2025). Antibody-drug conjugates in cancer therapy: Applications and future advances. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1516419"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kapoor, A.K., Ellis, C.S., Pandey, D., Allison, D.B., and Myint, Z.W. (2024). Case report: Enfortumab vedotin induced refractory DKA and multi organ failure\u2014A rare fatal adverse event. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1332478"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Kobayashi, T., Izuchi, T., Otake, K., Ando, M., Handa, T., Miyata, T., Sugiyama, M., Onoue, T., and Hagiwara, D. (2024). Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: A prospective study with immortal time bias correction. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1490042"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: A retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.70427","article-title":"Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma","volume":"63","author":"Liu","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"eabb7495","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1210\/er.2018-00092","article-title":"Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review","volume":"40","author":"Gebauer","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2023.16875","article-title":"Clinical Care for People Who Survive Childhood Cancer: A Review","volume":"330","author":"Bhatia","year":"2023","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e240101","DOI":"10.1530\/ERC-24-0101","article-title":"Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: A prospective study from a single tertiary center","volume":"31","author":"Barlas","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e71818","DOI":"10.1002\/cam4.71818","article-title":"Endocrinologist-Led Management of Endocrine Immune-Related Adverse Events: Real-World Evidence Supporting the Japan Endocrine Society Guidelines","volume":"15","author":"Nishihama","year":"2026","journal-title":"Cancer Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","article-title":"American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"ii35","DOI":"10.1093\/ejendo\/lvaf066","article-title":"EndoCompass project: Research roadmap for endocrine causes and consequences of cancer","volume":"193","author":"Carroll","year":"2025","journal-title":"Eur. J. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"112723","DOI":"10.1016\/j.mce.2025.112723","article-title":"Integrative advances in endocrine oncology: From unique glimpses to familiar themes","volume":"613","author":"Ezzat","year":"2026","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/3\/347\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:53:17Z","timestamp":1782467597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/3\/347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medsci14030347"],"URL":"https:\/\/doi.org\/10.3390\/medsci14030347","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}